Eosinophilic Esophagitis Market Insight, Epidemiology and Market Forecast -2030
Eosinophilic Esophagitis Market
The EoE market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted EoE market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current EoE treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Eosinophilic Esophagitis Market Outlook
The Eosinophilic Esophagitis market outlook of the report builds a detailed comprehension of the historical, current, and forecasted EoE market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Eosinophilic Esophagitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Eosinophilic Esophagitis market in the 7MM is expected to change in the study period 2018–2030.
Currently, the 3 “D”s (“Drugs, Diet, and Dilation”) are considered the fundamental components of treatment. The first two components, which involve the use of proton pump inhibitors, corticosteroids, immunosuppressants, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases, whereas endoscopic dilation is reserved for esophageal strictures. Herein, the most important aspects of eosinophilic Esophagitis pathophysiology will be reviewed, in addition to evidence for the various treatments. There are currently no drugs approved by the Food and Drug Administration for the treatment of EoE.
Key Findings
This section includes a glimpse of the Eosinophilic Esophagitis market in the 7MM. The market size of Eosinophilic Esophagitis in the seven major markets was found to be USD 430.9 million in 2020.
The United States: Market Outlook
This section provides the total Eosinophilic Esophagitis market size and market size by therapies of Eosinophilic Esophagitis in the United States.
The United States accounts for the highest market size of Eosinophilic Esophagitis in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
PPIs are useful as a first-line treatment for patients with EoE. Initial PPI doses of 20-40 mg or 1 mg/kg per dose are given twice daily in adults and children, respectively. The reported response rates to PPI therapy in the EoE population can vary widely from 30–70%. This is likely due to distinct clinical scenarios but there are currently no clinical features that discern a patient who will respond to PPI monotherapy.
Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.
Bougie and balloon dilation is the only endoscopic treatment available for EoE. It is performed in patients with persistent dysphagia resistant to medical treatment in whom remission of inflammation has been achieved and in patients with severe dysphagia and a history of food impaction.
Request for sample pages @ Eosinophilic Esophagitis Market Size
Table of contents
1. Key Insights
2. Report Introduction
3. Eosinophilic Esophagitis Market Overview at a Glance
3.1. Market Share (%) Distribution of Eosinophilic Esophagitis in 2018
3.2. Market Share (%) Distribution of Eosinophilic Esophagitis in 2030
4. Eosinophilic Esophagitis Patient Split at a Glance
4.1. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2018
4.2. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2030
5. Executive Summary of Eosinophilic Esophagitis
6. Disease Background and Overview
6.1. Introduction
6.2. Clinical Manifestation
6.3. Risk factors associated with EoE
6.4. Phenotypes, Endotypes and Genotype correlation in Eosinophilic Esophagitis
6.5. Pathophysiology
6.6. Diagnosis
6.6.1. Differential Diagnosis
6.6.2. Complexities in EoE Diagnosis
7. Treatment
8. Guidelines for Management of EoE
8.1. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
8.2. European statements and recommendations on the management of EoE
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. 7MM Total Diagnosed Prevalent Population of Eosinophilic Esophagitis
9.3. Epidemiology of Eosinophilic Esophagitis
9.4. The United States
9.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the United States
9.4.2. Gender-specific cases of Eosinophilic Esophagitis in the United States
9.4.3. Age-specific cases of Eosinophilic Esophagitis in the United States
9.5. EU5
9.5.1. Germany
9.5.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Germany
9.5.1.2. Gender-specific cases of Eosinophilic Esophagitis in Germany
9.5.1.3. Age-specific Cases of Eosinophilic Esophagitis in Germany
9.5.2. France
9.5.2.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in France
9.5.2.2. Gender-specific cases of Eosinophilic Esophagitis in France
9.5.2.3. Age-specific Cases of Eosinophilic Esophagitis in France
9.5.3. Italy
9.5.3.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Italy
9.5.3.2. Gender-specific cases of Eosinophilic Esophagitis in Italy
9.5.3.3. Age-specific Cases of Eosinophilic Esophagitis in Italy
9.5.4. Spain
9.5.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Spain
9.5.4.2. Gender-specific cases of Eosinophilic Esophagitis in Spain
9.5.4.3. Age-specific Cases of Eosinophilic Esophagitis in Spain
9.5.5. United Kingdom
9.5.5.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the UK
9.5.5.2. Gender-specific cases of Eosinophilic Esophagitis in the United Kingdom
9.5.5.3. Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom
9.6. Japan
9.6.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Japan
9.6.1.2. Gender-specific cases of Eosinophilic Esophagitis in Japan
9.6.1.3. Age-specific Cases of Eosinophilic Esophagitis in Japan
10. Organizations contributing toward the fight against EoE
11. Patient Journey
12. Case Report
13. Marketed Drug
13.1. Jorveza: Dr Falk Pharma GmbH
13.2. Drug Description
13.3. Regulatory Milestone
13.4. Safety and Efficacy
13.5. Side Effect
13.6. Product Profile
14. Emerging Therapies
14.1. Key Cross Competition
14.2. Budesonide Oral Suspension: Takeda
14.2.1. Drug Description
14.2.2. Other Development Activities
14.2.3. Clinical Development
14.2.4. Clinical Trial Information
14.2.5. Safety and Efficacy
14.2.6. Product Profile
14.3. Dupilumab: Regeneron Pharmaceuticals/Sanofi
14.3.1. Drug Description
14.3.2. Other Development Activities
14.3.3. Clinical Development
14.3.4. Clinical Trial Information
14.3.5. Safety and Efficacy
14.3.6. Product Profile
14.4. Cendakimab: Bristol-Myers Squibb
14.4.1. Drug Description
14.4.2. Other Development Activities
14.4.3. Clinical Development
14.4.4. Clinical Trial Information
14.4.5. Safety and Efficacy
14.4.6. Product Profile
14.5. APT-1011: Ellodi Pharmaceuticals
14.5.1. Drug Description
14.5.2. Other Development Activities
14.5.3. Clinical Development
14.5.4. Clinical trial information
14.5.5. Safety and Efficacy
14.5.6. Product Profile
14.6. Benralizumab: AstraZeneca
14.6.1. Drug Description
14.6.2. Other Development Activities
14.6.3. Clinical Development
14.6.4. Clinical trial information
14.6.5. Product Profile
14.7. Lirentelimab: Allakos
14.7.1. Drug Description
14.7.2. Other Development Activities
14.7.3. Clinical Development
14.7.4. Clinical Trial Information
14.7.5. Safety and Efficacy
14.7.6. Product Profile
15. Other Promising Therapies
15.1. ESO-101: EsoCap AG
15.1.1. Drug Description
15.1.2. Other Development Activities
15.1.3. Clinical Development
15.1.4. Clinical trial information
15.1.5. Product Profile
15.2. Etrasimod: Arena Pharmaceutical
15.2.1. Drug Description
15.2.2. Other Development Activities
15.2.3. Clinical Development
15.2.4. Clinical Trial Information
15.2.5. Product Profile
15.3. Mepolizumab: GlaxoSmithKline
15.3.1. Drug Description
15.3.2. Clinical Development
15.3.3. Clinical Trial Information
15.3.4. Product Profile
16. Eosinophilic Esophagitis: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Size of Eosinophilic Esophagitis in 7MM
16.3. Market Outlook
16.4. United States Market Size
16.4.1. Total Market Size of Eosinophilic Esophagitis in the United States
16.4.2. Market Size of Eosinophilic Esophagitis by Therapies in United States
16.4.3. Market Size of Eosinophilic Esophagitis by Class in the United States
16.5. EU-5 Market Size
16.5.1. Germany
16.5.1.1. Total Market size of Eosinophilic Esophagitis in Germany
16.5.1.2. Market Size of Eosinophilic Esophagitis by Therapies in Germany
16.5.1.3. Market Size of Eosinophilic Esophagitis by Class in Germany
16.5.2. France
16.5.2.1. Total Market size of Eosinophilic Esophagitis in France
16.5.2.2. Market Size of Eosinophilic Esophagitis by Therapies in France
16.5.2.3. Market Size of Eosinophilic Esophagitis by Class in France
16.5.3. Italy
16.5.3.1. Total Market size of Eosinophilic Esophagitis in Italy
16.5.3.2. Market Size of Eosinophilic Esophagitis by Therapies in Italy
16.5.3.3. Market Size of Eosinophilic Esophagitis by Class Italy
16.5.4. Spain
16.5.4.1. Total Market size of Eosinophilic Esophagitis in Spain
16.5.4.2. Market Size of Eosinophilic Esophagitis by Therapies in Spain
16.5.4.3. Market Size of Eosinophilic Esophagitis by Class in Spain
16.5.5. United Kingdom
16.5.5.1. Total Market size of Eosinophilic Esophagitis in United Kingdom
16.5.5.2. Market Size of Eosinophilic Esophagitis by Therapies in United Kingdom
16.5.5.3. Market Size of Eosinophilic Esophagitis by Class in the United Kingdom
16.6. Japan
16.6.1. Total Market size of Eosinophilic Esophagitis in Japan
16.6.2. Market Size of Eosinophilic Esophagitis by Therapies in Japan
16.6.3. Market Size of Eosinophilic Esophagitis by Class in Japan
17. KOL Views
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Unmet Needs
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/